<DOC>
	<DOCNO>NCT02937233</DOCNO>
	<brief_summary>This phase 1 trial one administration Zika Virus Purified Inactivated Vaccine ( ZPIV ) . The trial conduct placebo control , double-blind , randomize allocation study product . There four group study . Each group test different vaccine schedule .</brief_summary>
	<brief_title>Zika Virus Purified Inactivated Vaccine ( ZPIV ) Accelerated Vaccination Schedule Study</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Age 1850 year old . 2 . Ability willingness provide inform consent . 3 . Assessment understanding : completion questionnaire prior first screening procedure ; verbally demonstrate understanding questionnaire item answer incorrectly . 4 . Available duration trial . 5 . Good general health show medical history , physical exam , screen laboratory test . 6 . The following laboratory parameter : Hematology Hemoglobin ≥10.5 g/dL woman ; ≥11 g/dL men Absolute Neutrophil Count ( ANC ) : ≥1000/mm3 Platelets : 125,000 550,000/mm3 Chemistry Creatinine : &lt; 1.1 x upper limit normal ( ULN ) AST : &lt; 1.25 x ULN ALT : &lt; 1.25 x ULN Normal urinalysis Negative urine glucose . Negative trace urine protein . Negative trace urine hemoglobin ( trace hemoglobin present dipstick , microscopic urinalysis within institutional range ) . 7 . All female participant must willing undergo serum urine beta human chorionic gonadotropin pregnancy test time point indicate Schedule Procedures must test negative prior vaccination . 8 . All sexually active male ( unless anatomically sterile ) must willing use effective method contraception ( consistent condom use ) day first vaccination Week 12 . 9 . If woman childbearing potential , commit use effective method contraception sexually active men Week 12 , include : Condoms ( male female ) without spermicide . Diaphragm cervical cap spermicide . Intrauterine device . Hormonal contraception . Successful vasectomy male partner ( consider successful woman report male partner [ 1 ] documentation azoospermia microscopy , [ 2 ] vasectomy 2 year ago resultant pregnancy despite sexual activity postvasectomy ) . Not reproductive potential , undergone hysterectomy , bilateral oophorectomy , tubal ligation . 1 . History known flavivirus infection previous receipt flavivirus vaccine . 2 . Positive serology HIV1 , Hepatitis B surface antigen , antihepatitis C virus antibody prior enrollment . 3 . Planned travel area active Zika virus transmission study period . 4 . Recent ( within 3 week ) travel area active Zika virus transmission . 5 . Current plan participation another clinical trial experimental agent study period . 6 . Pregnant lactating . 7 . Any condition , include clinically significant acute chronic medical condition , , opinion investigator , participation would best interest subject ( eg , compromise wellbeing ) could prevent , limit , confound protocolspecified assessment . 8 . Use anticancer , antituberculosis medication consider significant investigator within previous 6 month . 9 . Receipt liveattenuated vaccine within previous 60 day plan receipt within 60 day vaccination Investigational Product ( within 14 day live attenuated influenza vaccine [ LAIV ] ) ; receipt vaccine ( e.g. , influenza , pneumococcal ) , allergy treatment antigen injection tuberculin skin test within previous 14 day plan receipt within 14 day vaccination Investigational Product 10 . Receipt blood transfusion bloodderived product within previous 3 month . 11 . Previous severe local systemic reaction vaccination . 12 . History splenectomy 13 . History seizure last 3 year ( participant history seizures neither required medication seizure 3 year exclude ) 14 . Known autoimmune disease 15 . Asthma mild , wellcontrolled asthma . Exclude participant : 1 . Use bronchodilator ( beta 2 agonist ) daily , 2 . In past year ( follow ) : . Had &gt; 1 exacerbation symptom treat oral steroid ii . Routinely used moderate high dose inhale corticosteroid ( e.g. , equivalent 250 mcg fluticasone ; 400 mcg budesonide ; 500 mcg beclomethasone ; 1000 mcg triamcinolone/flunisolide , daily dose ) theophylline iii . Needed emergency care , urgent care , hospitalization , intubation asthma c. Prophylactic bronchodilator use prior exercise exclusionary 16 . Diabetes mellitus type 1 type 2 , include case control diet alone . ( Not exclude : history isolate gestational diabetes . ) 17 . Thyroidectomy , thyroid disease require medication last 12 month 18 . Angioedema within last 3 year episodes consider serious require medication within last 2 year 19 . Uncontrolled Hypertension : 1 . If person diagnose hypertension screen previously , exclude hypertension well control . Well control hypertension define blood pressure consistently ≤ 140 mm Hg systolic ≤ 90 mm Hg diastolic , without medication , isolate , brief instance high reading , must ≤ 150 mm 2 . If person NOT diagnose hypertension screen previously , exclude systolic blood pressure ≥ 150 mm Hg enrollment diastolic blood pressure ≥ 90 mm Hg enrolment 20 . Bleeding disorder diagnose doctor ( e.g . factor deficiency , coagulopathy , platelet disorder require special precaution ) 21 . Malignancy ( Not exclude : participant surgical excision subsequent observation period investigator 's estimation reasonable assurance sustain cure unlikely recur study period ) 22 . Psychiatric condition compromise safety participant precludes compliance protocol , specifically exclude person psychosis within past 3 year , ongoing risk suicide , history suicide attempt gesture within past 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Zika</keyword>
	<keyword>Vaccine</keyword>
	<keyword>ZPIV</keyword>
</DOC>